86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details
臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
Showing 1 to 4 of 4 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-024585-22-DE (EUCTR) | 01/12/2016 | 17/08/2016 | What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise ca ... | What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? - Ferinject® for iron deficiency in IPAH patients What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise ca ... | Idiopathic or familial pulmonary arterial hypertension MedDRA version: 19.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Idiopathic or familial pulmonary arterial hypertension MedDRA version: 19.0;Level: PT;Classification ... | Trade Name: Ferinject Product Name: Ferinject INN or Proposed INN: FERRIC CARBOXYMALTOSE | Imperial College Academic Healthsciences Centre | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Germany;United Kingdom | ||
| 2 | NCT01847352 (ClinicalTrials.gov) | February 2013 | 1/5/2013 | Iron Status and Hypoxic Pulmonary Vascular Responses | Effect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous Iron Effect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by In ... | Lung Hypoxia;Pulmonary Arterial Hypertension;Iron Deficiency | Drug: Intravenous administration of ferric carboxymaltose;Other: Subacute hypoxic exposures | University of Oxford | National Institute for Health Research, United Kingdom;British Heart Foundation | Completed | 18 Years | N/A | Both | 31 | N/A | United Kingdom |
| 3 | EUCTR2010-024585-22-GB (EUCTR) | 25/03/2011 | 25/02/2011 | What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise ca ... | What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency? - Ferinject® for iron deficiency in IPAH patients What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise ca ... | Idiopathic or familial pulmonary arterial hypertension MedDRA version: 18.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Idiopathic or familial pulmonary arterial hypertension MedDRA version: 18.0;Level: PT;Classification ... | Trade Name: Ferinject Product Name: Ferinject INN or Proposed INN: Ferric carboxymaltose | Imperial College Academic Healthsciences Centre | NULL | Not Recruiting | Female: yes Male: yes | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ... | Germany;United Kingdom | |||
| 4 | EUCTR2010-023233-30-NL (EUCTR) | 13/12/2010 | 06/10/2010 | ‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAH ‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treati ... | ‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAH ‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treati ... | Objective: To evaluate the effects of intravenous iron suppletion in iron deficient IPAH patients.Study design: Intervention studyStudy population: Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiencyIntervention:Patients receive a weekly iron bolus infusion until iron levels are restored (correction phase). Then a maintenance dose is given once per month (maintenance phase) until the endpoint after 20 weeks. MedDRA version: 12.1;Level: LLT;Classification code 10064909;Term: Idiopathic (IPAH) Objective: To evaluate the effects of intravenous iron suppletion in iron deficient IPAH patients.St ... | Trade Name: Ferinject Product Name: Ferric carboxymaltose Product Code: RVG 33865 | VU university medical center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Netherlands |